J&J Profit Tops, Tylenol Recall Hurts Sales
Johnson & Johnson (JNJ) reported fourth-quarter earnings above Wall Street analyst estimates on Tuesday, but sales missed expectations and the diversified medical and personal care products maker guided 2013 earnings lower. The maker of a wide array of medical products from over-the-counter medications like Tylenol to surgical implants such as hip and knee replacements said Q4 EPS rose 5% to $1.19, beating expectations by 2 cents. Sales climbed 8%
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here